[Miocamycin in the prevention and treatment of cutaneous infections in the emergency service].
The efficacy and tolerability of a new macrolide, Myocamycine, were assessed in the anti-infectious prophylaxis of lacerations and contusions and in the treatment of already infected wounds or phlegmons. A total of 175 patients were treated. Side effects induced the suspension of treatment in 8% of cases while the drug proved effective in preventing the infection of wounds at risk in 98% and curing existing infections in 100%.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy* / Q000517:prevention & control; D004630:Emergencies; D005260:Female; D006801:Humans; D007933:Leucomycins / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015644:Miocamycin; D012874:Skin Diseases, Infectious / Q000188:drug therapy* / Q000517:prevention & control; D014947:Wounds and Injuries / Q000150:complications*
D007933:Leucomycins; D015644:Miocamycin
La miocamicina nella profilassi e nel trattamento delle infezioni cutanee in Pronto Soccorso.